Business / Finance

RSS

BIOTECH Development Partners provides funds to Biomagnetics

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced it has begun receiving funds from a biotech-oriented investment group called BIOTECH Development Partners, LLC.

20 Apr 2011

Quest Diagnostics first quarter revenues increase to $1.8 billion

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced that for the first quarter ended March 31, 2011, adjusted income from continuing operations was $164 million, or $1.00 per diluted share, compared to $182 million, or $0.99 per diluted share in 2010.

From Quest Diagnostics 20 Apr 2011

Forest acquires worldwide rights to novel antiarrhythmic agent azimilide

Forest Laboratories, Inc. today announced that its wholly-owned subsidiary Forest Laboratories Holdings Limited and Blue Ash Therapeutics, LLC have entered into an asset purchase agreement, pursuant to which Forest has acquired worldwide rights to azimilide, a novel antiarrhythmic agent originally developed by Procter & Gamble Pharmaceuticals.

20 Apr 2011

Sartorius first-quarter sales revenue increases 14.4% to 172.1 million euros

Sartorius started off fiscal 2011 with double-digit growth rates in order intake, sales revenue and profit. "We are currently seeing dynamic growth fueled by both divisions and all business regions. Compared with the year-earlier quarter, though also slightly below average, we have achieved highly encouraging rates of increase in revenue and profit," said CEO Dr. Joachim Kreuzburg.

From Sartorius 20 Apr 2011

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.

20 Apr 2011

Alnylam, Precision NanoSystems enter collaboration for discovery of novel small lipid nanoparticles

Precision NanoSystems, Inc. and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the two companies have formed an exclusive collaboration focused on the discovery and development of novel lipid nanoparticles, known as small lipid nanoparticles ("sLNPs"), using microfluidics technology.

From Precision NanoSystems Inc. 20 Apr 2011

Sagent prices initial public offering at $16.00 per share

Sagent Pharmaceuticals announced the upsizing and pricing of its initial public offering. The size of the offering has been increased from the previously announced 5,000,000 shares of common stock to 5,750,000 shares of common stock at a price to the public of $16.00 per share. The shares are scheduled to begin trading on The NASDAQ Global Market on April 20, 2011 under the ticker symbol "SGNT."

20 Apr 2011

Ampio raises $12.732 million through private placement of common stock

Ampio Pharmaceuticals, Inc. announced today the successful completion of a private placement from which Ampio received gross proceeds of $12.732 million.

20 Apr 2011

TCI forecasts cancer vaccine market to approach $3 billion in 2015

Technology Catalysts International (TCI), leading global consultants to the pharmaceutical industry, announced that research on cancer trends and development has identified cancer vaccines as a viable treatment option for a variety of cancers that currently have ineffective treatments. The potential of the cancer vaccine market is forecast to approach $3 billion in 2015.

20 Apr 2011

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.12 in the fourth quarter of fiscal 2011.

19 Apr 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson today announced sales of $16.2 billion for the first quarter of 2011, an increase of 3.5% as compared to the first quarter of 2010.

19 Apr 2011

Circassia closes $98 million fundraising for lead allergy programmes

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has closed a GBP60 million fundraising. The funding round was led by Imperial Innovations, and included investments from other existing shareholders, including Invesco Perpetual.

19 Apr 2011

BioSante, Aduro BioTech enter license agreement for GVAX cancer vaccines

Aduro BioTech, a clinical-stage immunotherapy company, has licensed GVAX Pancreas Cancer Vaccine and GVAX Prostate Cancer Vaccine BioSante Pharmaceuticals, Inc. in exchange for milestone and royalty payments after commercialization.

19 Apr 2011

Essilor first quarter revenue increases to €1,027.6 million

Essilor International, the world leader in ophthalmic optics, today announced that consolidated revenue for the three months ended March 31, 2011 totaled €1,027.6 million, an increase of 13.4% over the year-earlier period.

19 Apr 2011

BioSante licenses Pancreas and Prostate cancer vaccines to Aduro BioTech

BioSante Pharmaceuticals, Inc. today announced it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in combination with Aduro's proprietary vaccine platform based on Listeria monocytogenes (Lm).

19 Apr 2011

Molina Healthcare reports net income of $17.4 million for first quarter 2011

Molina Healthcare, Inc. today reported its financial results for the first quarter ended March 31, 2011.

19 Apr 2011

Stericycle acquires Healthcare Waste Solutions

Stericycle, Inc. announced today that it had completed its pending acquisition of Healthcare Waste Solutions, Inc. following an agreement with the U.S. Department of Justice and the State of New York providing clearance for the transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

19 Apr 2011

ValueOptions enters alliance with LifeSpeak

ValueOptions® is pleased to announce an alliance with LifeSpeak Inc. that is designed to proactively help member employees around the world work, learn and thrive. Through this partnership, ValueOptions® expands its health and wellness product portfolio to include the Life Speak online video library.

18 Apr 2011

Tenet Healthcare board to review Community Health Systems' revised all-cash proposal

Tenet Healthcare Corporation today confirmed that it has received a revised proposal from Community Health Systems, Inc. to acquire all of the outstanding shares of Tenet for $6.00 per share in cash.

18 Apr 2011

OnPoint Medical Diagnostics becomes wholly-owned subsidiary of Vertical Health Solutions

OnPoint Medical Diagnostics, Inc., a privately-held Minnesota corporation, and Vertical Health Solutions, Inc., a Florida corporation, have completed a reverse merger. Pursuant to the merger agreement, OnPoint has become a wholly-owned subsidiary of Vertical Health Solutions (VHS) and shall constitute the sole business and operations of VHS.

18 Apr 2011